Head and Neck CancerPhase 2NCT00005087
Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer
A Phase 2 study testing filgrastim, cisplatin and paclitaxel in people with Head and Neck Cancer, run by Radiation Therapy Oncology Group at 235 sites in 2 countries.
Trial summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Head and Neck Cancer
- What is being tested?
- filgrastim, cisplatin and paclitaxel
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 105 participants
- Where
- 235 sitesin 2 countries
- Study dates
- Mar 2000to Nov 2013
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically proven locally recurrent primary squamous cell cancer (SCC) of the head and neck or second primary SCC of the head and neck
- More than 1 prior recurrence allowed if the first recurrence occurred at least 6 months after completion of prior radiotherapy
- Disease must be confined to the head and neck (above the clavicles)
- No primary SCC of the nasopharynx or salivary gland
- Prior irradiation of 45-75 Gy to the majority (75% or greater) of tumor volume
- Entire tumor volume must be included in a treatment field that limits the total spinal cord dose (prior and anticipated) to 50 Gy
- Prior radiotherapy records, including simulation and portal films, available in order to assure that cord tolerance is not exceeded
- Measurable disease
- Ineligible for complete surgical resection
- No distant metastases
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Zubrod 0 or 1
Life expectancy:
- No other concurrent illness that would limit survival
Hematopoietic:
- Granulocyte count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.5 mg/dL
- Serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) no greater than 2 times normal*
- Alkaline phosphatase no greater than 2 times normal*
- * Greater than 2 times normal allowed if no metastases by liver ultrasound or CT scan
Renal:
- Creatinine no greater than 1.5 mg/dL
Other:
- No other invasive malignancy within the past 2 years except in situ malignancies (e.g., carcinoma in situ of the cervix, carcinoma in situ of the breast, or nonmelanoma skin cancer)
- No other concurrent illness that would impair tolerance to therapy
- No grade 2 or worse pre-existing peripheral sensory neuropathy
- No hypersensitivity to E. coli derived products
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- Prior chemotherapy allowed as a component of the primary treatment
- No prior chemotherapy for recurrent disease
- At least 6 months since prior chemotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- See Disease Characteristics
- At least 6 months since prior radiotherapy
Surgery:
- See Disease Characteristics
Trial locations and contacts
235 sites in 2 countries.
235 sites in 2 countries
United States216 sites
Akron General Medical Center
Akron, Ohio, 44302
Akron City Hospital
Akron, Ohio, 44304
Cancer Center of Albany Medical Center
Albany, New York, 12208
Radiation Oncology Associates of Albuquerque
Albuquerque, New Mexico, 87109
Lehigh Valley Hospital
Allentown, Pennsylvania, 18105
Harrington Cancer Center
Amarillo, Texas, 79106
St. John's Medical Center
Anderson, Indiana, 46016
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
Anne Arundel Oncology Center
Annapolis, Maryland, 21401
Northwest Community Hospital
Arlington Heights, Illinois, 60005
Emory University Hospital - Atlanta
Atlanta, Georgia, 30322
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
Marlene and Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, 21201
Greater Baltimore Medical Center and Cancer Center
Baltimore, Maryland, 21204
Harbor Hospital Center
Baltimore, Maryland, 21215-1290
Sinai Hospital of Baltimore
Baltimore, Maryland, 21215
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231-2410
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
St. Luke's Hospital Cancer Center
Bethlehem, Pennsylvania, 18015
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, 35294-3300
Bloomington Hospital
Bloomington, Indiana, 47402
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
State University of New York Health Science Center at Brooklyn
Brooklyn, New York, 11203
New York Methodist Hospital
Brooklyn, New York, 11215
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
Vermont Cancer Center
Burlington, Vermont, 05405-0075
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
Cancer Center at the University of Virginia
Charlottesville, Virginia, 22908
Northwestern Memorial Hospital
Chicago, Illinois, 60611
Christ Hospital
Cincinnati, Ohio, 45219
Barrett Cancer Center
Cincinnati, Ohio, 45267-0502
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
University Hospitals of Cleveland
Cleveland, Ohio, 44106
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Finger Lakes Radiation Oncology Center
Clifton Springs, New York, 14432
Memorial Hospital Cancer Center
Colorado Springs, Colorado, 80909
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, 65203
Medical Center/John B. Amos Community Cancer Center
Columbus, Georgia, 31901
CCOP - Columbus
Columbus, Ohio, 43206
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210-1240
Mount Diablo Medical Center
Concord, California, 94524-4110
Northeast Medical Center
Concord, North Carolina, 28025
Geisinger Medical Center
Danville, Pennsylvania, 17822-2001
Mercy Fitzgerald Hospital
Darby, Pennsylvania, 19023
CCOP - Dayton
Dayton, Ohio, 45429
CCOP - Central Illinois
Decatur, Illinois, 62526
University of Colorado Cancer Center
Denver, Colorado, 80010
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Henry Ford Hospital
Detroit, Michigan, 48202
Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
City of Hope Comprehensive Cancer Center
Duarte, California, 91010-3000
Wendt Regional Cancer Center of Finley Hospital
Dubuque, Iowa, 52001
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, 07019
Pocono Cancer Center
East Stroudsburg, Pennsylvania, 18301
John F. Kennedy Medical Center
Edison, New Jersey, 08818
Trinitas Hospital - Jersey Street Campus
Elizabeth, New Jersey, 07201
Hurley Medical Center
Flint, Michigan, 48503
McLaren Regional Cancer Center
Flint, Michigan, 48532-3685
Saint Agnes Cancer Center
Fresno, California, 93720
California Cancer Center
Fresno, California, 93729-5100
University of Florida Health Science Center
Gainesville, Florida, 32610-0385
University of Texas Medical Branch
Galveston, Texas, 77555-0209
Saint Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502-1628
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, 54301
St. Vincent Hospital
Green Bay, Wisconsin, 54307-3508
Sutter Health West Cancer Research Group
Greenbrae, California, 94904
East Carolina University School of Medicine
Greenville, North Carolina, 27858-4354
CCOP - Greenville
Greenville, South Carolina, 29615
RMH Regional Cancer Center
Harrisonburg, Virginia, 22801
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
MBCCOP - Hawaii
Honolulu, Hawaii, 96813
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
Comprehensive Cancer Institute of Huntsville
Huntsville, Alabama, 35801
Huntsville Hospital System
Huntsville, Alabama, 35807
Cape Cod Hospital
Hyannis, Massachusetts, 02601
Veterans Affairs Medical Center - Indianapolis (Roudebush)
Indianapolis, Indiana, 46202
Clarian Health Partners Inc.
Indianapolis, Indiana, 46206-1367
Regional Cancer Center
Indianapolis, Indiana, 46219
Jackson-Madison County General Hospital
Jackson, Tennessee, 38301-3956
Florida Radiation Oncology Group
Jacksonville, Florida, 32207
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
CCOP - Kansas City
Kansas City, Missouri, 64131
Gundersen Lutheran Medical Foundation
La Crosse, Wisconsin, 54601
Wilford Hall Medical Center
Lackland Air Force Base, Texas, 78236-5300
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756-0002
Central Baptist Hospital
Lexington, Kentucky, 40503
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
Loma Linda University Medical Center
Loma Linda, California, 92354
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822
Monmouth Medical Center
Long Branch, New Jersey, 07740-6395
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90025-1781
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
James Graham Brown Cancer Center
Louisville, Kentucky, 40202
Louisville Radiation Oncology
Louisville, Kentucky, 40215
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, 79410-1894
Southern Wisconsin Radiotherapy Center
Madison, Wisconsin, 53713
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792
Merle M. Mahr Cancer Center
Madisonville, Kentucky, 42431
Elliot Regional Cancer Center
Manchester, New Hampshire, 03103
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Marquette General Hospital
Marquette, Michigan, 49855
Marshfield Clinic
Marshfield, Wisconsin, 54449
Loyola University Medical Center
Maywood, Illinois, 60153
Health First Holmes Regional Medical Center
Melbourne, Florida, 32901-3276
University of Tennessee Cancer Institute
Memphis, Tennessee, 38103
Community Memorial Hospital
Menomonee Falls, Wisconsin, 53051
Veterans Affairs Medical Center - Miami
Miami, Florida, 33125
Sylvester Cancer Center, University of Miami
Miami, Florida, 33136
Baptist Hospital of Miami
Miami, Florida, 33256-2110
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
MidMichigan Medical Center - Midland
Midland, Michigan, 48670
South Jersey Regional Cancer Center
Millville, New Jersey, 08332
Columbia Hospital
Milwaukee, Wisconsin, 53211
St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Veterans Affairs Medical Center - Milwaukee (Zablocki)
Milwaukee, Wisconsin, 53295
Trinity Cancer Care Center
Minot, North Dakota, 58701
MBCCOP - Gulf Coast
Mobile, Alabama, 36688
Alabama Oncology, LLC
Montgomery, Alabama, 36106-3657
Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital
Mount Holly, New Jersey, 08060
Ball Memorial Hospital
Muncie, Indiana, 47303-3499
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232-5671
Cancer Institute of New Jersey
New Brunswick, New Jersey, 38103-2807
Hospital of St. Raphael
New Haven, Connecticut, 06511
Tulane University School of Medicine
New Orleans, Louisiana, 70112-2699
MBCCOP - LSU Medical Center
New Orleans, Louisiana, 70112
CCOP - Ochsner
New Orleans, Louisiana, 70121
Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Newark Beth Israel Medical Center
Newark, New Jersey, 07112
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
St. Anthony Hospital
Oklahoma City, Oklahoma, 73101
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Methodist Hospital Cancer Center - Omaha
Omaha, Nebraska, 68114
Nebraska Health System
Omaha, Nebraska, 68198-7460
MD Anderson Cancer Center Orlando
Orlando, Florida, 32806-2134
Bay Medical Center
Panama City, Florida, 32401
Gulf Coast Cancer Treatment Center
Panama City, Florida, 32405-4587
Lutheran General Cancer Care Center
Park Ridge, Illinois, 60068
Huntington Cancer Center
Pasadena, California, 91105
Bayshore Medical Center
Pasadena, Texas, 77504
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104-4283
Veterans Affairs Medical Center - Philadelphia
Philadelphia, Pennsylvania, 19104
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107-5541
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Albert Einstein Cancer Center
Philadelphia, Pennsylvania, 19141-3098
Foundation for Cancer Research and Education
Phoenix, Arizona, 85013
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15213-3489
Mercy Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15219
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224
Champlain Valley Physicians Hospital Medical Center
Plattsburgh, New York, 12901
Robert and Beverly Lewis Family Cancer Care Center
Pomona, California, 91767
Atlantic City Medical Center
Pomona, New Jersey, 08240
Maine Medical Center
Portland, Maine, 04102
CCOP - Columbia River Program
Portland, Oregon, 97225
Naval Medical Center, Portsmouth
Portsmouth, Virginia, 23708-2197
Vassar Brothers Medical Center
Poughkeepsie, New York, 12601
Roger Williams Medical Center/BUSM
Providence, Rhode Island, 02908-4735
All Saints Cancer Center
Racine, Wisconsin, 53405
Rapid City Regional Hospital
Rapid City, South Dakota, 57709
Reading Hospital and Medical Center
Reading, Pennsylvania, 19612-6052
Bon Secours - St. Mary's Hospital
Richmond, Virginia, 23226
Massey Cancer Center
Richmond, Virginia, 23298-0058
Valley Hospital
Ridgewood, New Jersey, 07450
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
James P. Wilmot Cancer Center
Rochester, New York, 14642
Regional Radiation Oncology Center at Rome
Rome, Georgia, 30165
CCOP - Beaumont
Royal Oak, Michigan, 48073-6769
William Beaumont Hospital
Royal Oak, Michigan, 48073
Radiation Oncology Center - Sacramento
Sacramento, California, 95816
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Peninsula Regional Medical Center
Salisbury, Maryland, 21801
University of Utah Health Sciences Center
Salt Lake City, Utah, 84132
Latter Day Saints Hospital
Salt Lake City, Utah, 84143
Radiation Medical Group, Inc.
San Diego, California, 92101
UCSF Comprehensive Cancer Center
San Francisco, California, 94143-0128
O'Connor Hospital
San Jose, California, 95128
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
Sarasota Radiation and Medical Oncology Center
Sarasota, Florida, 34233
Mercy Hospital Cancer Center - Scranton
Scranton, Pennsylvania, 18501
Virginia Mason Medical Center
Seattle, Washington, 98111
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Deaconess Medical Center
Spokane, Washington, 99204
Cancer Research for the Ozarks
Springfield, Missouri, 65807
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807
Mallinckrodt Institute of Radiology
St Louis, Missouri, 63108
St. Louis University Health Sciences Center
St Louis, Missouri, 63110-0250
Dixie Regional Medical Center
St. George, Utah, 84770
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
Syracuse, New York, 13217
Tallahassee Memorial Healthcare
Tallahassee, Florida, 32308
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612-9497
CCOP - Toledo Community Hospital
Toledo, Ohio, 43623-3456
Community Medical Center
Toms River, New Jersey, 08755
David Grant Medical Center
Travis Air Force Base, California, 94535
St. Francis Medical Center
Trenton, New Jersey, 08629
William Beaumont Hospital - Troy
Troy, Michigan, 48098
St. John Health System
Tulsa, Oklahoma, 74104
CCOP - Oklahoma
Tulsa, Oklahoma, 74136
DCH Cancer Treatment Center
Tuscaloosa, Alabama, 35401
Associated Radiologists, P.A.
Warren Township, New Jersey, 07059
Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188
Schiffler Cancer Center
Wheeling, West Virginia, 26003
Wilkes Barre General Hospital
Wilkes-Barre, Pennsylvania, 18764
CCOP - Christiana Care Health Services
Wilmington, Delaware, 19899
CCOP - Southeast Cancer Control Consortium
Winston-Salem, North Carolina, 27104-4241
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, 27157-1082
Yakima Valley Memorial Hospital
Yakima, Washington, 98902
Riverhill Radiation Oncology
Yonkers, New York, 10701
York Cancer Center
York, Pennsylvania, 17403
Canada19 sites
Tom Baker Cancer Center - Calgary
Calgary, Alberta, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
CHUS-Hopital Fleurimont
Fleurimont, Quebec, J1H 5N4
Northeastern Ontario Regional Cancer Centre, Sudbury
Greater Sudbury, Ontario, P3E 5J1
Nova Scotia Cancer Centre
Halifax, Nova Scotia, B3H 1V7
Cancer Care Ontario-Hamilton Regional Cancer Centre
Hamilton, Ontario, L8V 5C2
Kingston Regional Cancer Centre
Kingston, Ontario, K7L 5P9
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, N6A 4L6
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2L 4MI
McGill University
Montreal, Quebec, H2W 1S6
Ottawa Regional Cancer Centre
Ottawa, Ontario, K1H 1C4
Centre Hospitalier Universitaire de Quebec
Québec, Quebec, G1R 2J6
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Newfoundland Cancer Treatment and Research Foundation
St. John's, Newfoundland and Labrador, A1B 3V6
Northwestern Ontario Regional Cancer Centre, Thunder Bay
Thunder Bay, Ontario, P7A 7T1
Toronto Sunnybrook Regional Cancer Centre
Toronto, Ontario, M4N 3M5
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
About this study
Official title: Phase II Study of Paclitaxel and Cisplatin in Combination With Split Course Concomitant Hyperfractionated Re-Irradiation in Patients With Recurrent Squamous Cell Cancer of the Head and Neck
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Radiation therapy uses high-energy x-rays to damage tumor cells.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel, cisplatin, and filgrastim combined with radiation therapy in treating patients who have locally recurrent head and neck cancer and have received previous treatment with radiation therapy.
Read the detailed description
OBJECTIVES:
- Determine the median, one-year, and long-term (defined as two-year) disease-free survival and overall survival in patients with previously irradiated locally recurrent squamous cell cancer of the head and neck treated with paclitaxel, cisplatin, and filgrastim (G-CSF) combined with radiotherapy.
- Determine the rates of acute and late toxic effects of this regimen in these patients.
- Determine the pattern of disease progression in patients treated with this regimen.
OUTLINE: Patients undergo radiotherapy twice daily (4-6 hours apart) on days 1-5. Patients receive paclitaxel IV over 1 hour beginning immediately after completion of the first fraction of radiotherapy and completing less than 3 hours before starting the second fraction of radiotherapy on days 1-5. Patients receive cisplatin IV over 30 minutes beginning immediately after completion of paclitaxel infusion on days 1-5 and filgrastim (G-CSF) subcutaneously on days 6-13. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients who initially respond to therapy but develop a recurrence with a resectable lesion (inside or outside the retreatment field) may undergo surgical resection.
Patients are followed at 4 weeks after completion of radiotherapy, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 34 months.
- Conditions
- Head and Neck Cancer
- Being tested
- filgrastim, cisplatin, paclitaxel, conventional surgery, radiation therapy
- Keywords
- recurrent metastatic squamous neck cancer with occult primary, metastatic squamous neck cancer with occult primary squamous cell carcinoma, stage I squamous cell carcinoma of the lip and oral cavity, stage II squamous cell carcinoma of the lip and oral cavity, stage III squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the lip and oral cavity, stage I squamous cell carcinoma of the oropharynx, stage II squamous cell carcinoma of the oropharynx, stage III squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the oropharynx, stage I squamous cell carcinoma of the hypopharynx, stage II squamous cell carcinoma of the hypopharynx, stage III squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the hypopharynx, stage I squamous cell carcinoma of the larynx, stage II squamous cell carcinoma of the larynx, stage III squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the larynx, stage I squamous cell carcinoma of the paranasal sinus and nasal cavity, stage II squamous cell carcinoma of the paranasal sinus and nasal cavity
- Medical subject headings
- Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
filgrastimBiological
cisplatinDrug
paclitaxelDrug
conventional surgeryProcedure or surgery
radiation therapyRadiation
| Study group | Role | What they receive |
|---|---|---|
| Radiation (BID) and chemotherapy | Experimental | Radiation (BID), cisplatin and paclitaxel given on days 1-5 (Monday-Friday) in weeks 1, 3, 5 and 7. G-CSF given on days 6-13. Receives: Biological: filgrastim; Drug: cisplatin; Drug: paclitaxel; Procedure: conventional surgery; Radiation: radiation therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Measured: From registration to 1 year
Secondary outcomes (3)
Disease-free Survival
Measured: From registration to 1 year
Grade 4-5 toxicity
Measured: From one year after the start of radiation therapy to last follow-up.
Pattern of failure (local-regional, distant, new primary, death)
Measured: From registration to last follow-up.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startMar 2000
- Primary completionNov 2004
- Study completionNov 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Head and Neck CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 105 participants (actual)
Sponsor and investigators
- Lead sponsor
- Radiation Therapy Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Corey J. Langer, MD, Study chair, Fox Chase Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00005087
- Sponsor's protocol ID
- RTOG-9911
- Other IDs
- CDR0000067705
- Status last verified
- Nov 2015
- First submitted
- 6 Apr 2000
- Last updated
- 17 Nov 2015
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007 Oct 20;25(30):4800-5. doi: 10.1200/JCO.2006.07.9194.
PubMed 17947728Horwitz EM, Harris J, Langer CJ, et al.: Concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): update of RTOG 9911 . [Abstract] J Clin Oncol 23 (Suppl 16): A-5577, 519s, 2005.
Horwitz EM, Harris J, Langer CJ, et al.: Phase II study of paclitaxel and cisplatin in combination with split course concomitant hyperfractioned re-irradiation in patients with recurrent squamous cell cancer of the head and neck : results of RTOG 99-11. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-119, S72, 2005.
Langer CJ, Harris J, Horwitz E, et al.: Phase II trial of concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): results of RTOG 9911. [Abstract] J Clin Oncol 22 (Suppl 14): A-5509, 490s, 2004.
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase II Study of Paclitaxel and Cisplatin in Combination With Split Course Concomitant Hyperfractionated Re-Irradiation in Patients With Recurrent Squamous Cell Cancer of the Head and Neck
- ClinicalTrials.gov ID
- NCT00005087
- Acronym / sponsor ID
- RTOG-9911
- Conditions
- Head and Neck Cancer
- Keywords
- recurrent metastatic squamous neck cancer with occult primary, metastatic squamous neck cancer with occult primary squamous cell carcinoma, stage I squamous cell carcinoma of the lip and oral cavity, stage II squamous cell carcinoma of the lip and oral cavity, stage III squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the lip and oral cavity, stage I squamous cell carcinoma of the oropharynx, stage II squamous cell carcinoma of the oropharynx
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 105 participants (actual)
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Mar 2000
- Primary completion
- Nov 2004 (actual)
- Study completion
- Nov 2013 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Radiation therapy uses high-energy x-rays to damage tumor cells.
PURPOSE: Phase II trial to study the effectiveness of paclitaxel, cisplatin, and filgrastim combined with radiation therapy in treating patients who have locally recurrent head and neck cancer and have received previous treatment with radiation therapy.
Detailed description
OBJECTIVES:
- Determine the median, one-year, and long-term (defined as two-year) disease-free survival and overall survival in patients with previously irradiated locally recurrent squamous cell cancer of the head and neck treated with paclitaxel, cisplatin, and filgrastim (G-CSF) combined with radiotherapy.
- Determine the rates of acute and late toxic effects of this regimen in these patients.
- Determine the pattern of disease progression in patients treated with this regimen.
OUTLINE: Patients undergo radiotherapy twice daily (4-6 hours apart) on days 1-5. Patients receive paclitaxel IV over 1 hour beginning immediately after completion of the first fraction of radiotherapy and completing less than 3 hours before starting the second fraction of radiotherapy on days 1-5. Patients receive cisplatin IV over 30 minutes beginning immediately after completion of paclitaxel infusion on days 1-5 and filgrastim (G-CSF) subcutaneously on days 6-13. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients who initially respond to therapy but develop a recurrence with a resectable lesion (inside or outside the retreatment field) may undergo surgical resection.
Patients are followed at 4 weeks after completion of radiotherapy, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study within 34 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Radiation (BID) and chemotherapy | Experimental | Biological: filgrastim, Drug: cisplatin, Drug: paclitaxel, Procedure: conventional surgery, Radiation: radiation therapyRadiation (BID), cisplatin and paclitaxel given on days 1-5 (Monday-Friday) in weeks 1, 3, 5 and 7. G-CSF given on days 6-13. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| filgrastim | Biological | Radiation (BID) and chemotherapy |
| cisplatin | Drug | Radiation (BID) and chemotherapy |
| paclitaxel | Drug | Radiation (BID) and chemotherapy |
| conventional surgery | Procedure or surgery | Radiation (BID) and chemotherapy |
| radiation therapy | Radiation | Radiation (BID) and chemotherapy |
Primary outcome
Overall Survival
Time frame: From registration to 1 year
3 secondary outcomes
Disease-free Survival
Time frame: From registration to 1 year
Grade 4-5 toxicity
Time frame: From one year after the start of radiation therapy to last follow-up.
Pattern of failure (local-regional, distant, new primary, death)
Time frame: From registration to last follow-up.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2015.
- Results publication: PubMed 17947728Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, Wong S, Ang K. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007 Oct 20;25(30):4800-5. doi: 10.1200/JCO.2006.07.9194.
- Results publicationHorwitz EM, Harris J, Langer CJ, et al.: Concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): update of RTOG 9911 . [Abstract] J Clin Oncol 23 (Suppl 16): A-5577, 519s, 2005.
- Results publicationHorwitz EM, Harris J, Langer CJ, et al.: Phase II study of paclitaxel and cisplatin in combination with split course concomitant hyperfractioned re-irradiation in patients with recurrent squamous cell cancer of the head and neck : results of RTOG 99-11. [Abstract] Int J Radiat Oncol Biol Phys 63 (2 Suppl 1): A-119, S72, 2005.
- Results publicationLanger CJ, Harris J, Horwitz E, et al.: Phase II trial of concurrent split course hyperfractionated radiotherapy (Hfx RT), cisplatin (DDP) and paclitaxel (P) in patients with recurrent, previously irradiated squamous cell carcinoma of the head and neck (SCCHN): results of RTOG 9911. [Abstract] J Clin Oncol 22 (Suppl 14): A-5509, 490s, 2004.
Related trials for Head and Neck Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Corey J. Langer, MD study chair
Fox Chase Cancer Center
235 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing filgrastim, cisplatin and paclitaxel in people with Head and Neck Cancer, run by Radiation Therapy Oncology Group at 235 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 235 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (time frame: From registration to 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00005087, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2015.